Episode Details
Back to Episodes
Pharmaceutical Executive Daily: China Approves Amgen's Tarlatamab for Previously Treated Extensive-Stage Small Cell Lung Cancer
Published 1 month, 1 week ago
Description
In today's Pharmaceutical Executive Daily, China approves Amgen's tarlatamab for previously treated extensive-stage small cell lung cancer, a large study identifies genetic predictors of GLP-1 weight loss efficacy and side effects, and Pharmaceutical Executive speaks with Phenomix CEO Mark Bagnall on the complex realities of GLP-1 usage that many patients don't anticipate.